Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

Company Profiles
Target Profiles
Product Profiles

Explore BCIQ profiles by entering a company name.

REQUEST A FREE TRIAL

Biodesix Inc.

Name: Biodesix Inc. - BioCentury Company Profiles - BCIQ
Creator: Biocentury

Headquarters: Boulder, CO, United States of America

Website: http://www.biodesix.com

Year Founded: 2006

Status: Public

Industry Sector: HealthServices

CEO: Scott Hutton

Number Of Employees: 273

Enterprise Value: $234,026,100

PE Ratio: -2.17

Exchange/Ticker 1: NASDAQ:BDSX

Exchange/Ticker 2: N/A

Latest Market Cap: $111,468,800

BioCentury | Apr 6, 2024

Finance

Public equity report: Contineum’s NASDAQ listing, Oruka’s financing-merger combo

Plus: Surrozen and Sutro raise cash, and Redx proposes to delist from London’s AIM

BioCentury | Feb 3, 2023

Management Tracks

Vessey to leave BMS in July

Plus: Nichols joining enGene as CEO and updates from Invivyd, Exai and more

BioCentury | Oct 29, 2020

Finance

Oct. 28 Quick Takes: Mirati raises $800M on KRAS data; BMS-insitro, Novartis-Molecular Partners, Genecast, Gracell, PureTech, Cerevel, Biodesix

Adagrasib readout helps Mirati build war chestResponse rate data in the closely-watched KRAS inhibitor race helped Mirati Therapeutics Inc. (NASDAQ:MRTX) raise $800 million in a follow-on via the sale

BioCentury | Mar 12, 2020

Management Tracks